Interventions for managing antiretroviral therapy-associated lipoatrophy.
OBJECTIVE
The purpose of this review is to summarize recent data on treatment options for highly active antiretroviral therapy-associated lipoatrophy.


RESULTS
Modification of antiretroviral therapy, especially replacing stavudine by abacavir, induces a slow but continuous increase in the subcutaneous fat mass in patients with highly active antiretroviral therapy-associated lipoatrophy. As part of an initial highly active antiretroviral therapy combination, tenofovir and emtricitabine cause less lipodystrophy than stavudine, but no data from controlled studies have yet assessed the effects of switching from older agents to tenofovir or emtricitabine. Novel antidiabetic drugs, glitazones, cause little improvement in highly active antiretroviral therapy-associated lipoatrophy, but increase blood cholesterol and triglyceride concentrations significantly, and thus cannot be recommended for the treatment of highly active antiretroviral therapy-associated lipoatrophy. Various reconstructive procedures have been used to correct facial lipoatrophy. Bioabsorbable fillers have been used successfully, but treatment with such fillers has to be repeated over time. Permanent fillers have a durable effect, but may be difficult or impossible to remove if complications occur. Furthermore, an optimal volume correction with a permanent filler now may prove to be an over-correction in the future, if the recovery process of adipose tissue continues after the modification of antiretroviral therapy.


CONCLUSIONS
The optimal choice of antiretroviral combination is of crucial importance for the prevention and treatment of highly active antiretroviral therapy-associated lipoatrophy. Switching from stavudine to abacavir causes a slow but continuous increase in the subcutaneous fat mass. Bioabsorbable skin fillers are the safest option for the reconstructive treatment of facial lipoatrophy.
Sutinen
Jussi
J
Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland. jussi.sutinen@hus.fi
D020341:Absorbable Implants; D000273:Adipose Tissue / Q000187:drug effects; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D005145:Face / Q000601:surgery; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D045162:Thiazolidinediones / Q000627:therapeutic use
D019380:Anti-HIV Agents; D045162:Thiazolidinediones